Maine 2023-2024 Regular Session

Maine Senate Bill LD1914

Introduced
5/9/23  
Refer
5/9/23  
Engrossed
4/3/24  

Caption

Resolve, to Establish the Commission to Study Pathways for Creating a Psilocybin Services Program in Maine

Impact

This legislation is poised to not only open avenues for psilocybin use but also to establish a system of oversight to ensure safety and efficacy. It includes mechanisms for training for medical providers and stipulations to protect public health. The act maintains that psilocybin can be legally provided under supervision, conditional on meeting outlined eligibility protocols. Moreover, it confines the operation of psilocybin service centers with specific regulatory guidance to preclude misuse or noncompliance.

Summary

LD1914, titled the Maine Psilocybin Health Access Act, proposes a framework for the provision and regulation of psilocybin products to adults aged 21 and older in Maine. The act establishes the Maine Psilocybin Advisory Board, mandated to evaluate medical, psychological, and scientific studies on psilocybin's efficacy in treating conditions like substance use disorders and depression. The board's findings and recommendations are to be reported to the Department of Health and Human Services, which is tasked with finalizing rules around psilocybin administration and integration services by July 2024.

Sentiment

The sentiment around LD1914 is generally positive, with advocates emphasizing its therapeutic potential and the necessary regulations that will accompany its implementation. However, there remains some concern regarding the impact of psilocybin use on public safety and potential misconceptions about its effects. Notable discussions revolve around ensuring robust guidelines that limit misuse while promoting accessibility for those in need of mental health treatment.

Contention

While overall support is evident, there are points of contention, especially regarding the balance between accessibility and regulatory oversight. Critics worry that without adequate regulation, the bill could lead to irresponsible practices or unintended consequences associated with psilocybin use. Additionally, the enforcement of integration sessions and the training requirements for service providers have been highlighted as areas needing careful consideration to ensure that clients receive safe and effective treatment.

Companion Bills

No companion bills found.

Previously Filed As

ME SF4485

Psilocybin therapeutic use program establishment

ME SF3971

Psilocybin therapeutic use program establishment

ME LD591

Resolve, Establishing the Commission to Study MaineCare Estate Recovery

ME LD169

Resolve, Establishing the Commission to Study MaineCare Estate Recovery

ME H2203

Establishing a pilot program for access to regulated psilocybin

ME A03845

Establishes the psilocybin assisted therapy pilot program; provides such program will be offered to veterans and first responders from New York state; establishes a psilocybin assisted therapy pilot program fund.

ME LD1347

Resolve, Establishing the Commission to Study the Maine Tort Claims Act

ME H1624

Establishing a task force to study equitable access to psilocybin and other entheogenic plants

ME S3148

"Psilocybin Behavioral Health Access and Services Act"; authorizes production and use of psilocybin to promote health and wellness.

ME LD1921

Resolve, to Establish the Commission to Study Pathways to Increase Efficiency in Resolving Legal Disputes Involving Housing Development Projects

Similar Bills

WV HB5588

Establish a regulated framework for the medical use of psilocybin to treat post-traumatic stress disorder (PTSD)

NH HB1796

allowing the use of psilocybin in approved clinical settings to treat qualified medical conditions.

IA HF978

A bill for an act relating to the production and administration of psilocybin, and providing penalties. (Formerly HF 620.)

IA HF620

A bill for an act relating to the production of psilocybin and the administration of psilocybin to persons with post-traumatic stress disorder, and providing penalties.(See HF 978.)

IA HF2085

A bill for an act relating to the production and administration of psilocybin and providing penalties.

NJ S3148

"Psilocybin Behavioral Health Access and Services Act"; authorizes production and use of psilocybin to promote health and wellness.

WA SB5921

Concerning psilocybin.

NH HB1809

(New Title) establishing a medical psilocybin advisory board to assess the advantages and disadvantages of the use of psilocybin for therapeutic purposes.